Sot Caller (epigenetic platform)

We filed a provisional patent for our new epigenetic platform, ”Sot Caller.” This technology has the potential of changing gene expression throughout the human body. In addition to new therapies we create with it, similliar technologies have produced licensing deals in the xB's. Our plan is to develop this modality with new treatments, and once reach sufficient data, we will be poised to execute partnerships with biotech and pharma.